Interleukin 1beta antibody, application thereof and interleukin 1beta detection kit
By providing high affinity and specific interleukin 1β antibodies, the problems of insufficient sensitivity and low specificity of detection of interleukin 1β in the prior art are solved, and efficient and specific detection effects are achieved.
Patent Information
- Application Number
- CN202510588851.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-08
- Publication Date
- 2025-06-03
- Estimated Expiration
- 2045-05-08
AI Technical Summary
In the prior art, when detecting interleukin 1β, the sensitivity is insufficient and the specificity is not high, and it is difficult to avoid crossing with interleukin 1α.
Provide high affinity and specific interleukin 1β antibodies to prepare interleukin 1β magnetic microparticle chemiluminescence detection products to ensure high affinity and specific recognition of the antibodies with interleukin 1β.
The sensitivity and specificity of detecting interleukin 1β is improved, and the intersection with interleukin 1α is avoided, achieving efficient detection effect.
Smart Images

Figure CN120081939A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to interleukin-1β antibodies and their applications, and interleukin-1β detection kits. Background Art
[0002] Inflammasome-activated caspase-1 becomes active through autoproteolysis, and then cleaves into pro-IL-1β and pro-IL-1851, and releases IL-1β. The rate-limiting step in the processing and secretion of IL-1β occurs during inflammasome activation. The activation of non-canonical inflammasomes is mediated by caspase-4 / 11, and K+ is closely related to both the canonical and non-canonical activation pathways of inflammasomes. In the canonical pathway, a decrease in intracellular K+ concentration is a necessary and sufficient step for caspase-1 activation; in the non-canonical pathway, activated caspase-11 triggers K+ efflux, and K+ efflux is required for NLRP3 activation. IL-1β is expressed under the activation of two signals and the guidance of inflammasomes, thereby exerting its biological role in promoting inflammation.
[0003] IL-1β is one of the most important mediators of inflammation and the host response to infection. When viral, bacterial, fungal, or parasitic infections occur, the level of IL-1β increases. Currently, commonly used clinical methods for detecting interleukin-1β include enzyme-linked immunosorbent assay, immunofluorescence assay, chemiluminescence assay, etc.
[0004] Studies have shown that the reference range of IL-1β in the plasma of healthy individuals is less than 12 pg / mL, which requires high sensitivity of the detection kit and high affinity of the antibody raw material.
[0005] IL-1 has two different molecular forms, one is IL-1α, and the other is called IL-1β; through sequence alignment analysis, the amino acid sequences of the two have about 26% homology, and there may be a certain degree of cross-reactivity during detection, which requires high specificity of the detection kit and antibody raw material. Summary of the Invention
[0006] The purpose of the present invention is to provide an interleukin-1β antibody, which has high affinity with interleukin-1β and can improve the sensitivity of detection products; the interleukin-1β antibody specifically recognizes interleukin-1β, avoiding cross-reactivity with interleukin-1α.
[0007] The present invention also provides the application of the interleukin-1β antibody in the preparation of a chemiluminescent immunoassay product for interleukin-1β using magnetic microparticles.
[0008] The present invention also provides a chemiluminescence immunoassay kit for detecting interleukin-1β using magnetic microparticles, which includes streptavidin magnetic microparticle solution, acridinium sulfonamide-labeled antibody solution, biotin-labeled antibody solution, calibrator and quality control product, so as to solve the problems in the prior art.
[0009] To achieve the above object, the present invention provides an interleukin-1β antibody, including antibody a or antibody b. Antibody a includes the following heavy chain complementarity determining regions: CDR1-VH with the amino acid sequence shown in SEQ ID NO.1, CDR2-VH with the amino acid sequence shown in SEQ ID NO.2, and CDR3-VH with the amino acid sequence shown in SEQ ID NO.3. Antibody a includes the following light chain complementarity determining regions: CDR1-VL with the amino acid sequence shown in SEQ ID NO.4, CDR2-VL with the amino acid sequence TAS, and CDR3-VL with the amino acid sequence shown in SEQ ID NO.5. Antibody b includes the following heavy chain complementarity determining regions: CDR1-VH with the amino acid sequence shown in SEQ ID NO.6, CDR2-VH with the amino acid sequence shown in SEQ ID NO.7, and CDR3-VH with the amino acid sequence shown in SEQ ID NO.8. Antibody b includes the following light chain complementarity determining regions: CDR1-VL with the amino acid sequence shown in SEQ ID NO.9, CDR2-VL with the amino acid sequence DAS, and CDR3-VL with the amino acid sequence shown in SEQ ID NO.10.
[0010] Preferably, the amino acid sequence of the heavy chain variable region of antibody a is shown in SEQ ID NO.11.
[0011] Preferably, the amino acid sequence of the light chain variable region of antibody a is shown in SEQ ID NO.12.
[0012] Preferably, the amino acid sequence of the heavy chain variable region of antibody b is shown in SEQ ID NO.13.
[0013] Preferably, the amino acid sequence of the light chain variable region of antibody b is shown in SEQ ID NO.14.
[0014] Preferably, the amino acid sequence of the light chain constant region of antibody a or antibody b is shown in SEQ ID NO.15, and the amino acid sequence of the heavy chain constant region of antibody a or antibody b is shown in SEQ ID NO.16.
[0015] Preferably, in any of the above, the antibody a is interleukin-1β monoclonal antibody 1, and the antibody b is interleukin-1β monoclonal antibody 2; further, the antibody a or antibody b is murine-derived.
[0016] The present invention also provides the coding sequences of the interleukin-1β antibodies described in any of the above.
[0017] Preferably, in any of the above, the coding sequence of the heavy chain variable region of the antibody a is the nucleotide sequence from the 1st to the 363rd nucleotide of the nucleotide sequence shown in SEQ ID NO.17.
[0018] Preferably, in any of the above, the coding sequence of the light chain variable region of the antibody a is the nucleotide sequence from the 1st to the 321st nucleotide of the nucleotide sequence shown in SEQ ID NO.18.
[0019] Preferably, in any of the above, the coding sequence of the heavy chain variable region of the antibody b is the nucleotide sequence from the 1st to the 375th nucleotide of the nucleotide sequence shown in SEQ ID NO.19.
[0020] Preferably, in any of the above, the coding sequence of the light chain variable region of the antibody b is the nucleotide sequence from the 1st to the 318th nucleotide of the nucleotide sequence shown in SEQ ID NO.20.
[0021] Preferably, in any of the above, the coding sequence of the heavy chain of the antibody a is the nucleotide sequence shown in SEQ ID NO.17.
[0022] Preferably, in any of the above, the coding sequence of the light chain of the antibody a is the nucleotide sequence shown in SEQ ID NO.18.
[0023] Preferably, in any of the above, the coding sequence of the heavy chain of the antibody b is the nucleotide sequence shown in SEQ ID NO.19.
[0024] Preferably, in any of the above, the coding sequence of the light chain of the antibody b is the nucleotide sequence shown in SEQ ID NO.20.
[0025] The present invention also provides a recombinant expression vector containing any of the above-described coding sequences. The recombinant expression vector contains the coding sequence of the antibody a or / and the coding sequence of the antibody b.
[0026] Preferably, in any of the above, the recombinant expression vector contains the coding sequence of the light chain variable region of the antibody a.
[0027] Preferably, in any of the above, the recombinant expression vector contains the coding sequence of the heavy chain variable region of the antibody a.
[0028] Preferably, in any of the above, the recombinant expression vector contains the coding sequence of the light chain variable region of antibody b.
[0029] Preferably, in any of the above, the recombinant expression vector contains the coding sequence of the heavy chain variable region of antibody b.
[0030] Preferably, in any of the above, the recombinant expression vector contains the coding sequence of the light chain of antibody a.
[0031] Preferably, in any of the above, the recombinant expression vector contains the coding sequence of the heavy chain of antibody a.
[0032] Preferably, in any of the above, the recombinant expression vector contains the coding sequence of the light chain of antibody b.
[0033] Preferably, in any of the above, the recombinant expression vector contains the coding sequence of the heavy chain of antibody b.
[0034] Preferably, in any of the above, the recombinant expression vector is constructed by ligating the coding sequences provided by the present invention to various expression vectors by conventional methods in the art. The expression vectors are various conventional vectors in the art, and any vector that can accommodate the nucleic acid molecule of the coding sequence is applicable to the present invention. The preferred expression vectors include: various plasmids, cosmids, phage or viral vectors, etc., such as pCDNA3.4, pCDNA3.1 series vectors, etc. The expression vector is preferably a eukaryotic expression vector, and the expression vector is preferably an expression vector suitable for mammalian cells.
[0035] The present invention also provides a host cell, which contains the recombinant expression vector described in any of the above or the coding sequence described in any of the above is integrated into the genome of the host cell. The host cell is preferably a mammalian cell.
[0036] In a preferred embodiment of the present invention, the recombinant expression vector is preferably a eukaryotic expression vector, and the host cell is preferably a mammalian cell. Further, the recombinant expression vector is preferably pCDNA3.4, and the host cell is preferably 293T cells.
[0037] The interleukin-1β antibody of the present invention can be either a monoclonal antibody prepared by a hybridoma or an antibody obtained by the recombinant expression vector described in any one of the above or the host cell described in any one of the above. The recombinant expression vector containing the antibody a heavy chain coding sequence and the recombinant expression vector containing the antibody a light chain coding sequence are co-transfected into a host cell (the host cell is preferably a mammalian cell) in equal proportions. The recombinant expression vector containing the antibody a heavy chain coding sequence and the recombinant expression vector containing the antibody a light chain coding sequence will undergo transcription, translation, and various modifications in the host cell to form an antibody, and the antibody a is obtained through purification; the recombinant expression vector containing the antibody b heavy chain coding sequence and the recombinant expression vector containing the antibody b light chain coding sequence are co-transfected into a host cell (the host cell is preferably a mammalian cell) in equal proportions. The recombinant expression vector containing the antibody b heavy chain coding sequence and the recombinant expression vector containing the antibody b light chain coding sequence will undergo transcription, translation, and various modifications in the cell to form an antibody, and the antibody b is obtained through purification. In the present invention, whether it is a monoclonal antibody obtained by a hybridoma or an antibody obtained by recombinant expression, it can specifically recognize interleukin-1β and avoid cross-reactivity with interleukin-1α.
[0038] The present invention provides the application of the interleukin-1β antibody described in any one of the above, or the coding sequence of the interleukin-1β antibody described in any one of the above, or the recombinant expression vector described in any one of the above, or the host cell described in any one of the above in the preparation of an interleukin-1β chemiluminescent immunoassay kit with magnetic microparticles.
[0039] The present invention provides an interleukin-1β detection kit, which includes a streptavidin magnetic microparticle solution, an acridinium sulfonamide-labeled antibody solution, a biotin-labeled antibody solution, a calibrator, and a quality control product.
[0040] The kit provided by the present invention can effectively detect interleukin-1β in the range of 2.5 to 2500 pg / mL. Further, the detection range is preferably 8 to 1000 pg / mL.
[0041] Preferably, in any one of the above, the acridinium sulfonamide-labeled antibody solution contains the interleukin-1β antibody described in any one of the above, and the interleukin-1β antibody is labeled with acridinium sulfonamide.
[0042] Preferably, in any one of the above, the biotin-labeled antibody solution contains the interleukin-1β antibody described in any one of the above, and the interleukin-1β antibody is labeled with biotin.
[0043] Preferably, in any one of the above, the interleukin-1β antibodies contained in the acridinium sulfonamide-labeled antibody solution and the biotin-labeled antibody solution are different.
[0044] In a preferred embodiment of the present invention, the interleukin-1β antibody in the acridinesulfonamide-labeled antibody solution is antibody a, and the interleukin-1β antibody in the biotin-labeled antibody solution is antibody b; in a preferred embodiment of the present invention, the interleukin-1β antibody in the acridinesulfonamide-labeled antibody solution is antibody b, and the interleukin-1β antibody in the biotin-labeled antibody solution is antibody a.
[0045] Preferably, any one of the above, the biotin-labeled antibody solution contains 0.2 to 2 μg / mL of the interleukin-1β antibody; more preferably, 0.2, 0.5, 1.0, 1.5, 2.0 μg / mL and the ranges therebetween.
[0046] Preferably, any one of the above, the acridinesulfonamide-labeled antibody solution contains 0.2 to 2 μg / mL of the interleukin-1β antibody. More preferably, 0.2, 0.5, 1.0, 1.5, 2.0 μg / mL and the ranges therebetween.
[0047] Preferably, any one of the above, the interleukin-1β antibody diluent is a 10 to 50 mM Tris-HCl buffer containing BSA, and each 100 mL of the diluent contains 0.1 to 1.0 g of BSA. More preferably, in the Tris-HCl buffer, the concentration of the Tris-HCl buffer is 10, 20, 30, 40, 50 mM and the ranges therebetween; more preferably, each 100 mL of the diluent contains 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0 g and the ranges therebetween of BSA. The interleukin-1β antibody diluent is the diluent of the acridinesulfonamide-labeled antibody solution or the diluent of the biotin-labeled antibody solution.
[0048] Preferably, any one of the above, the concentration of the streptavidin magnetic particle solution is 0.1 to 1.0 mg / mL, and further preferably 0.1, 0.5, 1.0 mg / mL and the ranges therebetween.
[0049] Preferably, any one of the above, the calibrator is a freeze-dried product of interleukin-1β, and preferably also includes freeze-dried excipients. Preferably, it is reconstituted with pure water when in use.
[0050] Preferably, any one of the above, the quality control product is a freeze-dried product of interleukin-1β, and preferably also includes freeze-dried excipients. Preferably, it is reconstituted with pure water when in use.
[0051] Preferably, any of the above-mentioned interleukin-1β freeze-dried products is interleukin-1β prepared by using the prior art or a protein product of commercialized interleukin-1β. The present invention uses interleukin-1β of Beijing Baixinyi Biotechnology Co., Ltd., but it should be noted that the present invention is not limited to the source and preparation method of interleukin-1β.
[0052] Preferably, any of the above-mentioned freeze-drying excipients are conventional freeze-drying excipients in the prior art. Preferably, they include saccharides such as trehalose, sucrose, and lactose; preferably, they include polyhydric alcohols such as mannitol and sorbitol; preferably, they include amino acids such as glycine and histidine; preferably, they include proteins such as bovine serum albumin (BSA); preferably, they include gelatin; preferably, they include buffer systems such as phosphate buffer solution (PBS) and Tris-HCl; preferably, they include surfactants such as Tween-20 and polyvinylpyrrolidone (PVP); preferably, they include preservatives such as Proclin 300 and sodium azide.
[0053] Compared with the prior art, the present invention has the following beneficial effects: The interleukin-1β antibody provided by the present invention has good specificity, high affinity for interleukin-1β, avoids cross-reaction with interleukin-1α, and can be used for preparing a chemiluminescence immunoassay product for detecting interleukin-1β with magnetic microparticles.
[0054] The interleukin-1β detection kit provided by the present invention has the advantages of automated detection, high sensitivity, strong specificity, and large throughput. Description of the Drawings
[0055] Figure 1 It is the electrophoresis pattern of the monoclonal antibody of interleukin-1β in the preferred embodiment 1 of the present invention.
[0056] Figure 2 It is the interleukin-1β detection kit in the preferred embodiments 2 and 3 of the present invention.
[0057] Figure 3 It is the interleukin-1β detection reagent in the preferred embodiments 2 and 3 of the present invention. Detailed Description of the Invention
[0058] The present invention will be further described in detail below through specific embodiments.
[0059] It should be noted that the "variable region" or "variable domain" of an antibody refers to the amino-terminal domain of the heavy or light chain of the antibody. The variable domain of the heavy chain can be referred to as "VH". The variable domain of the light chain can be referred to as "VL". These domains are generally the most variable parts of the antibody and contain the antigen-binding sites. The variable region of the light or heavy chain is composed of framework regions interrupted by three hypervariable regions called "complementary determining regions" or "CDRs". The framework regions of the antibody, that is, the framework regions constituting the combination of the light and heavy chains of the constituent elements, play a role in positioning and aligning the CDRs, which are mainly responsible for binding to the antigen.
[0060] The "framework" or "FR" region means the region outside those regions of the antibody variable domain that are defined as CDRs. Each antibody variable domain framework can be further subdivided into adjacent regions (FR1, FR2, FR3, and FR4) separated by CDRs.
[0061] Generally, the variable regions VL / VH of the heavy and light chains can be obtained by connecting the following numbered CDRs and FRs in the following combined arrangement: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
[0062] In the present invention, CDR1-VH, CDR2-VH, and CDR3-VH respectively refer to the three hypervariable regions of the heavy chain variable region. Correspondingly, CDR1-VL, CDR2-VL, and CDR3-VL respectively refer to the three hypervariable regions of the light chain variable region.
[0063] In a first aspect, the present invention provides an interleukin-1β antibody selected from antibody a and / or antibody b; Antibody a includes heavy chain complementary determining regions CDR1-VH, CDR2-VH, CDR3-VH whose amino acid sequences are successively shown as SEQ ID NO.1 to SEQ ID NO.3, and light chain complementary determining regions CDR1-VL whose amino acid sequences are successively shown as SEQ ID NO.4, light chain complementary determining region CDR2-VL with the amino acid sequence TAS, and light chain complementary determining region CDR3-VL whose amino acid sequence is shown as SEQ ID NO.5; Antibody b includes heavy chain complementary determining regions CDR1-VH, CDR2-VH, CDR3-VH whose amino acid sequences are successively shown as SEQ ID NO.6 to SEQ ID NO.8, and light chain complementary determining regions CDR1-VL whose amino acid sequences are successively shown as SEQ ID NO.9, light chain complementary determining region CDR2-VL with the amino acid sequence DAS, and light chain complementary determining region CDR3-VL whose amino acid sequences are successively shown as SEQ ID NO.10.
[0064] The amino acid sequences shown in SEQ ID NO.1 to SEQ ID NO.10 are shown in Table 1.
[0065] Table 1
[0066] The interleukin-1β antibody provided by the present invention has good specificity, high biological activity, and high affinity for interleukin-1β, and can be used to prepare products for detecting interleukin-1β.
[0067] In a preferred embodiment of the present invention, the antibody a comprises a heavy chain variable region and a light chain variable region whose amino acid sequences are shown in SEQ ID NO.11 and SEQ ID NO.12 in sequence; The antibody b comprises a heavy chain variable region and a light chain variable region whose amino acid sequences are shown in SEQ ID NO.13 and SEQ ID NO.14 in sequence; Preferably, the interleukin-1β antibody is murine.
[0068] The amino acid sequences shown in SEQ ID NO.11 to SEQ ID NO.14 are shown in Table 2.
[0069] Table 2
[0070] The heavy chain of the antibody a, i.e., interleukin-1β monoclonal antibody 1, is composed of the heavy chain variable region of interleukin-1β monoclonal antibody 1 and the constant region, and the light chain of interleukin-1β monoclonal antibody 1 is composed of the light chain variable region of interleukin-1β monoclonal antibody 1 and the constant region; the heavy chain of the antibody b, i.e., interleukin-1β monoclonal antibody 2, is composed of the heavy chain variable region of interleukin-1β monoclonal antibody 2 and the constant region, and the light chain of interleukin-1β monoclonal antibody 2 is composed of the light chain variable region of interleukin-1β monoclonal antibody 2 and the constant region. The amino acid sequence of the light chain constant region of the antibody a or antibody b is shown in SEQ ID NO.15, and the amino acid of the heavy chain constant region of the antibody a or antibody b is shown in SEQ ID NO.16, as shown in Table 3. Correspondingly, the amino acid sequence of the heavy chain of antibody a is composed of the amino acid sequences shown in SEQ ID NO.11 and SEQ ID NO.16 in sequence, and the amino acid sequence of the light chain of antibody a is composed of the amino acid sequences shown in SEQ ID NO.12 and SEQ ID NO.15 in sequence; the amino acid sequence of the heavy chain of antibody b is composed of the amino acid sequences shown in SEQ ID NO.13 and SEQ ID NO.16 in sequence, and the amino acid sequence of the light chain of antibody b is composed of the amino acid sequences shown in SEQ ID NO.14 and SEQ ID NO.15 in sequence.
[0071] Table 3
[0072] In a second aspect, the present invention provides the use of the interleukin-1β antibody in the preparation of a chemiluminescence immunoassay product for interleukin-1β using magnetic microparticles.
[0073] In a third aspect, the present invention provides an interleukin-1β detection kit, which includes a streptavidin magnetic microparticle solution, an acridinium sulfonamide-labeled antibody solution, a biotin-labeled antibody solution, calibrators, and quality control products.
[0074] Preferably, the concentration of the streptavidin magnetic microparticle solution is 0.1 - 1.0 mg / mL.
[0075] Preferably, the acridinium sulfonamide-labeled antibody solution contains the interleukin-1β antibody described in any one of the above, and the interleukin-1β antibody is labeled with acridinium sulfonamide, and the concentration of acridinium sulfonamide is recognized by a detection instrument.
[0076] Preferably, the acridinium sulfonamide-labeled antibody solution contains 0.2 - 2 μg / mL of the interleukin-1β antibody.
[0077] Preferably, the biotin-labeled antibody solution contains 0.2 - 2 μg / mL of the interleukin-1β antibody.
[0078] Preferably, the diluents for the biotin-labeled antibody solution and the acridinium sulfonamide-labeled antibody solution are 10 - 50 mM Tris-HCl buffer containing BSA, and each 100 mL of the diluent contains 0.1 - 1.0 g of BSA.
[0079] In a preferred embodiment of the present invention, the interleukin-1β antibody in the acridinium sulfonamide-labeled antibody solution is different from the interleukin-1β antibody contained in the biotin-labeled antibody solution.
[0080] In a preferred embodiment of the present invention, the antibody in the acridinium sulfonamide-labeled antibody solution is antibody a, antibody a is interleukin-1β monoclonal antibody 1, the antibody in the biotin-labeled antibody solution is antibody b, and antibody b is interleukin-1β monoclonal antibody 2.
[0081] In a preferred embodiment of the present invention, the antibody in the acridinium sulfonamide-labeled antibody solution is antibody b, and the antibody in the biotin-labeled antibody solution is antibody a.
[0082] Preferably, the calibrator is a freeze-dried product of interleukin-1β, and preferably also includes freeze-dried excipients. Preferably, it is reconstituted with pure water during use.
[0083] Preferably, the quality control product is a freeze-dried product of interleukin-1β, and preferably also includes freeze-dried auxiliary materials. Preferably, pure water is used for reconstitution during use.
[0084] Preferably, the interleukin 1β lyophilized product is interleukin 1β prepared by existing technology, or a commercialized interleukin 1β protein product. The present invention uses interleukin 1β from Beijing Baixinyi Biotechnology Co., Ltd., but the present invention is not limited to the source and preparation method of interleukin 1β.
[0085] Preferably, the lyophilization excipients are conventional lyophilization excipients in the prior art, preferably including sugars such as trehalose, sucrose, and lactose; preferably including polyols such as mannitol and sorbitol; preferably including amino acids such as glycine and histidine; preferably including proteins such as bovine serum albumin (BSA); preferably including gelatin; preferably including buffer systems such as phosphate buffered saline (PBS) and Tris-HCl; preferably including surfactants such as Tween-20 and polyvinyl pyrrolidone (PVP); preferably including preservatives such as Proclin 300 and sodium azide.
[0086] The interleukin 1β detection kit provided by the present invention has the advantages of automated operation, high sensitivity, strong specificity, large throughput, etc.
[0087] The reagent provided by the present invention is based on the principle of antigen-antibody reaction. After the interleukin 1β antibody is labeled with acridine sulfonamide, it is prepared into an acridine sulfonamide labeled antibody solution with a diluent; another antibody labeled with biotin interleukin 1β is contained in the biotin labeled antibody solution; based on the principle of antigen-antibody reaction, it can be detected by a matching instrument after the reaction is completed. If interleukin 1β exists in the sample, a double antibody sandwich structure is formed, and the instrument will detect a stronger light signal. If there is no interleukin 1β in the sample, the instrument will detect a weaker light signal. The load of the test object is predicted according to the intensity of the light intensity signal.
[0088] By using the kit provided by the present invention for testing, the test results can be obtained within 30 minutes of the entire process, which is fast and efficient, and helps medical personnel to obtain the test results in a timely manner, make comprehensive judgments based on the results, and take timely measures.
[0089] It should be noted that the diluent for the interleukin 1β antibody of the present invention is a 10-50 mM Tris-HCl buffer containing BSA, and each 100 mL of the diluent contains 0.1-1.0 g of BSA; unless otherwise specified in the following embodiments, preferably, the diluent for the interleukin 1β antibody is a 20 mM Tris-HCl buffer containing BSA, and each 100 mL of the diluent contains 0.5 g of BSA.
[0090] The method of preparing the interleukin 1β monoclonal antibody 1 shown in antibody a and the interleukin 1β monoclonal antibody 2 shown in antibody b of the present invention is a conventional monoclonal antibody preparation method in the prior art, which is briefly described as follows: (1) Animal immunization: A: Mix equal volumes of interleukin-1β purchased from Beijing Baixinyi Biotechnology Co., Ltd. with Freund's adjuvant to a suitable volume and emulsify it completely. Immunize mice by intraperitoneal injection. Each mouse is injected with 50 μg of immunogen, the injection volume is 100 μL / mouse, and the injection is once a week. B: After immunization for 4 times, the ELISA indirect method was used to coat interleukin-1β and test the titer of the antibody in the serum. Mice with an OD value greater than 1.0 detected by 16,000-fold serum dilution were screened.
[0091] (2) Preparation of monoclonal antibodies: A: The spleen cells of the screened mice were fused with myeloma cells, and the fused cells were plated and cultured using the limiting dilution method; B: Screen the monoclonal cell wells and culture and expand them. The monoclonal cell wells with the highest OD value detected in the cell culture supernatant are used as target hybridoma cells, culture and expand them, obtain hybridoma cell lines and freeze them; C: Isolation of antibody variable region genes from hybridoma cells using RT-PCR: After the hybridoma cells are homogenized, cell lysis buffer is added to extract RNA, RNA is precipitated from the aqueous phase with isopropanol, the precipitated RNA is washed after centrifugation, impurities are removed, and reverse transcription is performed after resuspension to obtain cDNA; D: PCR was performed using specific primers of mice known in the prior art, with the cDNA of hybridoma cells as the template to amplify the variable region genes of the heavy and light chains of the antibody. The 50 μL system contained 5 μL of cDNA, HotStarTaq Plus enzyme, dNTPs, and 0.5 μM specific primers. PCR amplification was carried out under the following conditions: pre-denaturation at 94 °C for 5 min; 94 °C for 30 s, 55 °C for 30 s, 72 °C for 50 s, for 35 cycles; 72 °C for 7 min; the obtained PCR products were identified by 1% agarose gel electrophoresis, the target fragments were recovered, sent for sequencing, and according to the antibody gene sequences obtained by sequencing, the amino acid sequences of the antibody variable regions shown in SEQ ID NO: 11-14 were further obtained; among them, the amino acid sequence of the light chain variable region of antibody a was shown in SEQ ID NO. 12, the amino acid sequence of the heavy chain variable region of antibody a was shown in SEQ ID NO. 11, the amino acid sequence of the light chain variable region of antibody b was shown in SEQ ID NO. 14, and the amino acid sequence of the heavy chain variable region of antibody b was shown in SEQ ID NO. 13. The amino acid sequence of the light chain constant region of antibody a or antibody b was shown in SEQID NO. 15, and the amino acid sequence of the heavy chain constant region of antibody a or antibody b was shown in SEQ ID NO. 16.
[0092] E: Construction of the expression vector of the monoclonal antibody: According to the antibody gene sequences obtained by sequencing in step D, the expression vector of the monoclonal antibody was constructed by conventional methods in the art. Homologous recombination arms were added to both ends of the antibody heavy chain variable region gene and both ends of the light chain variable region gene using homologous recombination primers. The expression plasmid containing the murine heavy and light chain IgG1 constant regions was linearized using double enzymes to generate homologous recombination arms; the variable region gene fragments with added homologous recombination arms and the linearized plasmid were ligated by homologous recombination to form a complete expression vector. The expression vector was pCDNA3.4, and the recombinant product was transformed into TOP10 Escherichia coli competent cells to amplify the plasmid; pCDNA3.4-antibody a heavy chain plasmid, pCDNA3.4-antibody a light chain plasmid, pCDNA3.4-antibody b heavy chain plasmid, and pCDNA3.4-antibody b light chain plasmid were obtained respectively.
[0093] The gene fragment encoding the heavy chain of antibody a inserted into the pCDNA3.4 vector was the nucleotide sequence shown in SEQ ID NO. 17, in which nucleotides 1-363 were the coding sequence of the heavy chain variable region of antibody a, and nucleotides 364-1335 were the coding sequence of the heavy chain constant region of antibody a.
[0094] The gene fragment encoding the light chain of antibody a inserted into the pCDNA3.4 vector is the nucleotide sequence shown in SEQ ID NO.18, wherein nucleotides 1 to 321 are the coding sequence for the variable region of the light chain of antibody a, and nucleotides 322 to 642 are the coding sequence for the constant region of the light chain of antibody a.
[0095] The gene fragment encoding the heavy chain of antibody b inserted into the pCDNA3.4 vector is the nucleotide sequence shown in SEQ ID NO.19, wherein nucleotides 1 to 375 are the coding sequence for the variable region of the heavy chain of antibody b, and nucleotides 376 to 1347 are the coding sequence for the constant region of the heavy chain of antibody b.
[0096] The gene fragment encoding the light chain of antibody b inserted into the pCDNA3.4 vector is the nucleotide sequence shown in SEQ ID NO.20, wherein nucleotides 1 to 318 are the coding sequence for the variable region of the light chain of antibody b, and nucleotides 319 to 639 are the coding sequence for the constant region of the light chain of antibody b.
[0097] F: Expression and purification of monoclonal antibody: Add the heavy and light chain expression plasmids of the monoclonal antibody obtained in step E to the Opti-Mem transfection medium at a ratio of 1:1. After thorough mixing, add transfection reagent PEI at 4 times the mass of DNA. After mixing, place it in the dark at room temperature for 10 min, and then add it to 293T cells. After incubation for 6 h, remove the transfection system, add FreeStyleTM293 expression medium, and collect the supernatant of the cell culture medium after 5 days of culture. Purify the supernatant of the cell culture medium by affinity purification (Protein A) to obtain the monoclonal antibody. The specific steps are as follows: (1) Centrifuge the expressed antibody supernatant at 2500×g for 10 min at room temperature to remove the precipitate; (2) Thoroughly wash the affinity purification column loaded with Protein A with 10 times the volume of binding buffer; (3) Pass the expressed supernatant through the purification column at a flow rate of 5 mL / min; (4) Wash the purification column thoroughly with 20 times the volume of the purification column of binding buffer; (5) Elute the purification column with 0.1M citric acid buffer at pH = 3.0 - 3.5 until the elution peak drops to the equilibrium state, and adjust the pH to 7.0 with 1M Tris-HCl buffer at pH = 9.0; (6) Concentrate the purified monoclonal antibody using a concentrator centrifugal column, use PBS as the buffer for antibody storage, and finally measure the concentration of the concentrated antibody using an ultra-micro ultraviolet spectrophotometer.
[0098] In a preferred embodiment of the present invention, the pCDNA3.4-antibody a heavy chain plasmid and the pCDNA3.4-antibody a light chain plasmid are co-transfected in a ratio of 1:1, and expressed and purified according to the method of step F to obtain antibody a. The pCDNA3.4-antibody b heavy chain plasmid and the pCDNA3.4-antibody b light chain plasmid are expressed and purified according to the method of step F to obtain antibody b. The obtained antibody a and antibody b are respectively verified by SDS-PAGE and ELISA according to the method described in Example 1. Both antibody a and antibody b show two characteristic bands of about 25KD and 50KD, which are the light chain and heavy chain of IgG respectively; the titers measured by the indirect ELISA method prove that both antibody a and antibody b can specifically recognize interleukin 1β and avoid cross-reaction with interleukin 1α.
[0099] The methods applied in the processes of antibody preparation, antibody gene sequencing, construction and identification of monoclonal antibody expression vectors in the present invention are all conventional methods in molecular biology. The relevant sequences such as primers involved can be obtained through the relevant information recorded in existing technologies such as gene databases or existing literature, or through the heavy chain target gene fragment or light chain target gene fragment of antibody a or b, such as obtained according to the nucleotide sequences shown in SEQ ID NO.17 to SEQ ID NO.20, which will not be elaborated here. Example 1
[0100] The interleukin 1β antibodies include: interleukin 1β monoclonal antibody 1 (antibody a), interleukin 1β monoclonal antibody 2 (antibody b). The variable region sequences of the above antibodies are shown in Table 2, and the constant region sequences are shown in Table 3.
[0101] Prepare a 12% SDS-PAGE gel by the conventional method, load 5 μg of the above antibody, and perform electrophoresis using a protein molecular weight standard as a reference. The results show that the two interleukin 1β antibodies show two characteristic bands of about 25KD and 50KD, which are the light chain and heavy chain of IgG respectively ( Figure 1 ). After scanning the bands, the antibody content is analyzed to be more than 90%.
[0102] Figure 1 Among them, lane 1 is Marker; lane 2 is interleukin 1β monoclonal antibody 1; lane 3 is interleukin 1β monoclonal antibody 2.
[0103] The antibodies used in the following examples are the same as those in Example 1.
[0104] Verification of the specificity of interleukin 1β monoclonal antibody 1 (antibody a): The titer was determined by the indirect ELISA method as follows: the ELISA plate was coated with interleukin 1α (purchased from Shanghai Aladdin Biochemical Technology Co., Ltd., catalog number rp174289) and interleukin 1β (purchased from Beijing Baixinyi Biotechnology Co., Ltd., catalog number A10C02), and the antibody a was diluted to 100, 10, 1, and 0.1 ng / mL, respectively, and the affinity of antibody a to different antigens was determined. The results are shown in Table 4.
[0105] Table 4
[0106] Verification of the specificity of interleukin-1β monoclonal antibody 2 (antibody b): The ELISA indirect method was used for determination, and the method was as follows: the ELISA plate was coated with interleukin-1α and interleukin-1β, respectively, and the antibody b was diluted to 100, 10, 1, and 0.1 ng / mL, respectively, and the affinity of antibody b to different antigens was determined. The results are shown in Table 5.
[0107] Table 5
[0108] Both antibody a and antibody b have a strong affinity for interleukin 1β, but no recognition for interleukin 1α.
[0109] Example 2 An interleukin 1β detection kit, such as Figure 2 , Figure 3 As shown, M is a streptavidin magnetic particle solution, B is a biotin labeled antibody solution, A is an acridine sulfonamide labeled antibody solution, CAL is a calibrator, and QC is a quality control product. The biotin labeled antibody solution includes a biotin labeled antibody a and a diluent. The acridine sulfonamide labeled antibody solution includes an acridine sulfonamide labeled antibody b and a diluent. The calibrator and quality control products are lyophilized products, including interleukin 1β and lyophilized excipients.
[0110] The diluent of the antibody a or antibody b is a 10-50 mM Tris-HCl buffer containing BSA, and each 100 mL of the diluent contains 0.1-1.0 g of BSA.
[0111] Example 3 Example 3 provides an interleukin 1β detection kit.
[0112] 1 Main Materials 1.1 Antibodies: Mouse anti-monoclonal antibodies are all interleukin-1β antibodies (antibody a and antibody b) described in the present invention, which are mouse monoclonal antibodies and are used to label biotin and acridine sulfonamide, respectively.
[0113] 1.2 Streptavidin magnetic particles: JSR.
[0114] 1.3 Acridine sulfonamide NSP-SA-NHS: Helison (Xiamen) Biotechnology Co., Ltd.
[0115] 1.4 Sulfo-NHS-LC-Biotin: Thermo.
[0116] 1.5 Other consumables: The chemiluminescence reagent rack set is provided by Clase Biotech (Chongqing) Co., Ltd.; commonly used reagents are all analytical grade reagents.
[0117] 1.6 Interleukin-1β: purchased from Beijing Baixinyi Biotechnology Co., Ltd., product number A10C02.
[0118] 2 Methods 2.1 Preparation of biotin-labeled antibody solution: The steps for preparing the biotin-labeled antibody solution are as follows: (1) Place 1 mg of the antibody to be labeled in a glass bottle and dilute it to 1 mg / mL with 0.01 M PBS (pH 7.2) buffer; (2) Take 14.85 μL of 10 mg / mL Sulfo-NHS-LC-Biotin solution and add it to the above-mentioned PBS buffer containing the antibody, mix well, and place it at room temperature in the dark for 1-2 hours; dialyze it with 0.01 M PBS (pH 7.2) buffer at 2-8°C in the dark for 5-10 times (each time with an interval of 2 hours); (3) Diluting the labeled product to 0.2-2.0 μg / mL with a diluent; the diluent is a 10-50 mM Tris-HCl buffer containing BSA, and each 100 mL of the diluent contains 0.1-1.0 g of BSA.
[0119] (4) Package the solution in 4 mL / bottle.
[0120] 2.2 Preparation of acridine sulfonamide labeled antibody solution: The steps for preparing the acridine sulfonamide labeled antibody solution are as follows: (1) Place 1 mg of the antibody to be labeled in a glass bottle and dilute it to 1 mg / mL with 0.1 M CBS (pH 9.0); (2) Take 45.5 μL of 2 mg / mL acridine sulfonamide NSP-SA-NHS and add it to the above CBS buffer containing the antibody, mix well, and place it at room temperature in the dark for 1-2 hours; dialyze it with 0.01 M PBS (pH 7.2) buffer at 2-8°C in the dark for 5-10 times (each time with an interval of 2 hours); (3) Dilute the labeled product with the diluent to 0.2 - 2.0 μg / mL; the diluent is a 10 - 50 mM Tris-HCl buffer containing BSA, and each 100 mL of the diluent contains 0.1 - 1.0 g of BSA.
[0121] (4) Aliquot at 4 mL per vial.
[0122] 2.3 Preparation of streptavidin magnetic particle solution: Dilute the streptavidin magnetic particles with the diluent to 0.1 - 1.0 mg / mL; aliquot at 6 mL per vial. The diluent is a 10 - 50 mM Tris-HCl buffer containing BSA, and each 100 mL of the diluent contains 0.1 - 1.0 g of BSA.
[0123] 2.4 Preparation of calibrators and quality control samples: Dilute interleukin-1β with the lyophilized solution to 2.5 - 2500 pg / mL (furthermore, it is preferred to prepare both calibrators and quality control samples with interleukin-1β at 2000 pg / mL), and aliquot at 0.6 mL per tube for lyophilization.
[0124] 2.5 Assembly of the kit: Refer to Figure 2 the layout, and place the biotin-labeled antibody solution, acridinium sulfonamide-labeled antibody solution, streptavidin magnetic particle solution, calibrators and quality control samples in their respective positions.
[0125] 2.6 Detection: Step 1: Take out the sample to be tested and equilibrate it to room temperature; preferably, the sample in the present invention is serum.
[0126] Step 2: Take out the refrigerated kit and install the Figure 3 indicated reagents in the reagent positions of the analyzer; Step 3: Reconstitute the calibrators and quality control samples with 600 μL of pure water, and then take 60 μL of the reconstituted calibrator or quality control sample and dilute it 10-fold with pure water; Step 4: Load the reconstituted and diluted calibrators, quality control samples and the sample to be tested onto the analyzer for detection; Step 5: The analyzer aspirates 50 - 100 μL of the calibrator, quality control sample or sample to be tested and adds it to the reaction cup, then adds 10 - 30 μL of the biotin-labeled antibody solution and 10 - 30 μL of the acridinium sulfonamide-labeled antibody, mixes well and incubates at 37°C for 5 - 25 min; Step 6: Add 10 - 50 μL of the streptavidin magnetic particle solution, mix well and incubate at 37°C for 2 - 10 min; Step 7: After washing, add the pre-excitation solution and the excitation solution, and the analyzer detects the luminescence value.
[0127] 3 Results: The analyzer automatically calibrates the built-in curve according to the detected luminescence value of the calibration product to obtain a calibration curve; the concentration values of interleukin-1β in the quality control product and the sample to be tested are calculated through the calibration curve.
[0128] In Example 3, the diluent is a 10 - 50 mM Tris-HCl buffer containing BSA, and each 100 mL of the diluent contains 0.1 - 1.0 g of BSA; the lyophilized solution is a 10 - 50 mM Tris-HCl buffer containing mannitol, BSA, and PVP, and each 100 mL of the diluent contains 1 - 10 g of mannitol, 0.1 - 1.0 g of BSA, and 0.02 - 0.5 g of PVP.
[0129] In Example 3, it is preferably to use the fully automatic chemiluminescence immunoassay analyzer of Kolas Biotechnology (Chongqing) Co., Ltd., model: Venus 100S.
[0130] Example 4 Example 4 provides the detection process of the kit.
[0131] Preparation of the sample to be tested: Dilute interleukin-1β and interleukin-1α to 5000, 1000, 200, 40, 8, 1.6 pg / mL respectively with 0.01 M PBS containing 1% BSA, and mix well.
[0132] Sample detection: Use the analyzer to detect the reconstituted calibration product, quality control product, and sample to be tested according to the method described in Example 3.
[0133] Example 4 uses the fully automatic chemiluminescence immunoassay analyzer of Kolas Biotechnology (Chongqing) Co., Ltd., model: Venus 100S. Use the built-in program of the instrument for calculation. Among them, the built-in curve fitting method: double logarithmic four-parameter curve fitting (automatically fitted by the device software system); calibration method: two-point segmented calibration; sample concentration calculation: obtained by substituting the detected optical signal of the sample into the calibration curve. Specifically, import the built-in curve and calibrate to obtain a calibration curve, and calculate the concentration values of interleukin-1β in the quality control product and the sample to be tested through the calibration curve. The test results are shown in Table 6.
[0134] Table 6 Test results of interleukin-1β and interleukin-1α
[0135] The above embodiments are merely examples given for clear illustration and are not limitations on the implementation manners. For those of ordinary skill in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to enumerate all implementation manners here. And the obvious changes or modifications derived therefrom still fall within the protection scope of the present invention.
Claims
1. An interleukin-1β antibody, including antibody a or antibody b, characterized in that: The antibody a comprises the following heavy chain complementary determining regions: CDR1-VH with an amino acid sequence as shown in SEQ ID NO.1, CDR2-VH with an amino acid sequence as shown in SEQ ID NO.2, and CDR3-VH with an amino acid sequence as shown in SEQ ID NO.3; The antibody a comprises the following light chain complementary determining regions: CDR1-VL with an amino acid sequence as shown in SEQ ID NO.4, CDR2-VL with an amino acid sequence of TAS, and CDR3-VL with an amino acid sequence as shown in SEQ ID NO.5; The antibody b comprises the following heavy chain complementary determining regions: CDR1-VH with an amino acid sequence as shown in SEQ ID NO.6, CDR2-VH with an amino acid sequence as shown in SEQ ID NO.7, and CDR3-VH with an amino acid sequence as shown in SEQ ID NO.8; The antibody b comprises the following light chain complementary determining regions: CDR1-VL with an amino acid sequence as shown in SEQ ID NO.9, CDR2-VL with an amino acid sequence of DAS, and CDR3-VL with an amino acid sequence as shown in SEQ ID NO.
10.
2. The interleukin-1β antibody according to claim 1, wherein The amino acid sequence of the heavy chain variable region of the antibody a is shown in SEQ ID NO.11; the amino acid sequence of the light chain variable region of the antibody a is shown in SEQ ID NO.
12.
3. The interleukin-1β antibody according to claim 1, wherein The amino acid sequence of the heavy chain variable region of the antibody b is shown in SEQ ID NO.13; the amino acid sequence of the light chain variable region of the antibody b is shown in SEQ ID NO.
14.
4. The coding sequence of the interleukin-1β antibody according to any one of claims 1 to 3, characterized in that The coding sequence of the heavy chain variable region of antibody a is nucleotides 1 to 363 of the nucleotide sequence shown in SEQ ID NO.17; the coding sequence of the light chain variable region of antibody a is nucleotides 1 to 321 of the nucleotide sequence shown in SEQ ID NO.18; the coding sequence of the heavy chain variable region of antibody b is nucleotides 1 to 375 of the nucleotide sequence shown in SEQ ID NO.19; the coding sequence of the light chain variable region of antibody b is nucleotides 1 to 318 of the nucleotide sequence shown in SEQ ID NO.
20.
5. The coding sequence according to claim 4, characterized in that The coding sequence of the antibody a heavy chain is the nucleotide sequence shown in SEQ ID NO.17; the coding sequence of the antibody a light chain is the nucleotide sequence shown in SEQ ID NO.18; the coding sequence of the antibody b heavy chain is the nucleotide sequence shown in SEQ ID NO.19; and the coding sequence of the antibody b light chain is the nucleotide sequence shown in SEQ ID NO.
20.
6. A recombinant expression vector comprising the coding sequence of claim 4 or 5.
7. A host cell, characterized in that The host cell comprises the recombinant expression vector of claim 6 or the coding sequence of claim 4 or 5 is integrated into the genome of the host cell.
8. Use of the interleukin 1β antibody according to any one of claims 1 to 3, or the coding sequence of the interleukin 1β antibody according to claim 4 or 5, or the recombinant expression vector according to claim 6, or the host cell according to claim 7 in the preparation of an interleukin 1β magnetic particle chemiluminescence detection product.
9. An interleukin-1β detection kit, comprising a streptavidin magnetic particle solution, an acridine sulfonamide labeled antibody solution, a biotin labeled antibody solution, a calibrator and a quality control product, characterized in that: The acridine sulfonamide-labeled antibody solution contains the interleukin 1β antibody according to any one of claims 1 to 3, and the interleukin 1β antibody is labeled with acridine sulfonamide; the biotin-labeled antibody solution contains the interleukin 1β antibody according to any one of claims 1 to 3, and the interleukin 1β antibody is labeled with biotin; the interleukin 1β antibodies contained in the acridine sulfonamide-labeled antibody solution and the biotin-labeled antibody solution are different.
10. The kit according to claim 9, characterized in that The interleukin 1β antibody diluent is a 10-50 mM Tris-HCl buffer containing BSA, and each 100 mL of the diluent contains 0.1-1.0 g of BSA; the biotin-labeled antibody solution contains 0.2-2 μg / mL of the interleukin 1β antibody; and the acridine sulfonamide-labeled antibody solution contains 0.2-2 μg / mL of the interleukin 1β antibody.
Citation Information
Patent Citations
Humanized anti-human-interleukin-1[belta] monoclonal antibody, preparation thereof and applications thereof
CN103588878A
Antibody combination for detecting interleukin 1-beta and application thereof
CN115353566A
Monoclonal antibody against rat interleukin-4 protein and application thereof
CN117143234A
